











**1. Cefepime does not induce PARP inhibitor sensitivity.** MTT viability assay of MB49 cells treated with vehicle (DMSO) or 2.5  $\mu\text{M}$  olaparib in combination with 80  $\mu\text{M}$  cefepime for 96 hours. p value by two-way ANOVA.



**Figure S2. Quantifications of select immunoblot images.** Quantifications of immunoblot images of specific targets from indicated figures obtained with ImageJ or Biorad ImageLab software.



**Figure S3. Cefepime treatment effects on immune cell populations *in vivo*.** Flow cytometry analysis of immune cell populations within B16 tumors isolated from WT mice treated with vehicle (veh), rabusertib (rab), cefepime (cef), or combination (combo) as in Fig. 4B. p values by unpaired t test.




**cefepime**



**meropenem**




**ceftazidime**



**cefazolin**



**ceftriaxone**



**penicillin G**

**Figure S4. Structures of  $\beta$ -lactam antibiotics for structure activity relationship potential.** Compilation of images adapted from the National Library of Medicine – National Center for Biotechnology PubChem database.